Abrocitinib

Abrocitinib is a JAK1 inhibitor (IC50 = 0.029 µM). It is selective for JAK1 over JAK2, JAK3, and TYK2 (IC50s = 0.803, >10, and 1.253 µM, respectively) and a panel of 40 kinases at 1 µM. Abrocitinib inhibits IFN-alpha-, IL-21-, or IL-27-induced phosphorylation of STAT3 (IC50s = 0.189, 0.511, and 0.271 µM, respectively) and IFN-gamma-induced phosphorylation of STAT1 (IC50 = 0.163 µM) in isolated human whole blood. It reduces paw edema in a rat model of adjuvant-induced arthritis when administered at doses of 1, 5, and 15 mg/kg. Formulations containing abrocitinib have been used in the treatment of atopic dermatitis.Formal Name: N-[cis-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide. CAS Number: 1622902-68-4. Synonyms: PF-04965842. Molecular Formula: C14H21N5O2S. Formula Weight: 323.4. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: soluble. lambdamax: 288 nm. SMILES: CN([C@H]1C[C@H](C1)NS(CCC)(=O)=O)C2=C3C(NC=C3)=NC=N2. InChi Code: InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+. InChi Key: IUEWXNHSKRWHDY-PHIMTYICSA-N.